Reduced- Compared with Standard-Dose Direct Oral Anticoagulant for Extended Treatment of Venous Thromboembolism: A Systematic Review and Meta-Analysis - PubMed
4 days ago
- #direct oral anticoagulant
- #venous thromboembolism
- #bleeding risk
- Reduced-dose DOACs (apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily) were compared to standard-dose DOACs (apixaban 5 mg twice daily or rivaroxaban 20 mg once daily) for extended VTE treatment.
- Reduced-dose DOACs showed similar rates of recurrent VTE (1.66% vs. 1.78%) compared to standard-dose DOACs.
- Major bleeding was less frequent with reduced-dose DOACs (1.16% vs. 1.96%), as was clinically relevant non-major bleeding (5.16% vs. 7.00%).
- Mortality rates were comparable between reduced-dose and standard-dose DOACs (4.91% vs. 5.81%).
- Reduced-dose DOACs appeared to lower recurrent VTE risk in males but increase risk in females, indicating a potential interaction with sex.
- The study concluded that reduced-dose DOACs have a similar risk of recurrent VTE and a lower risk of major and clinically relevant non-major bleeding compared to standard-dose DOACs for extended VTE treatment.